文献速递脑血管病

癌症患者缺血性卒中的机制:一项前瞻性研究

Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective Study.
PubMed 文献 · Ann Neurol · 2021-06-03

该前瞻性横断面研究于2016至2020年在2家医院纳入3组各50名成人,比较活动性实体瘤合并急性缺血性卒中、单纯卒中及单纯癌症患者的血液生物标志物与经颅多普勒微栓子。结果显示癌症合并卒中组凝血、血小板及内皮功能障碍标志物均高于对照组,微栓子检出率亦更高。

要点

  • 癌症合并卒中患者D-二聚体、sICAM-1、sVCAM-1及血栓调节蛋白高于两个对照组。
  • 癌症合并卒中组经颅多普勒微栓子检出率为32%,高于单纯卒中组16%和单纯癌症组6%(p=0.005)。
  • 癌症相关卒中机制涉及凝血激活、血小板活化与内皮功能障碍,并伴循环微栓子增多。

核心结论

  • 癌症相关卒中患者较匹配对照具有更高的凝血、血小板及内皮功能障碍标志物水平,且循环微栓子更多。

研究设计与样本

  • 前瞻性横断面研究,2016至2020年在2家医院开展,纳入3组各50名成人参与者。
  • 主组为活动性实体瘤癌症合并急性缺血性卒中患者,对照组为单纯急性缺血性卒中或单纯活动性癌症患者。
  • 单纯卒中组与单纯癌症组按年龄、性别及癌症类型(如适用)与癌症合并卒中组匹配。

主要发现

  • 所有研究生物标志物水平在组间存在差异。
  • 单因素组间比较中,癌症合并卒中组D-二聚体、sICAM-1、sVCAM-1及血栓调节蛋白水平高于两个对照组。
  • 癌症合并卒中组凝血酶-抗凝血酶水平高于单纯癌症组,P-选择素水平高于单纯卒中组。
  • 多因素分析结果与单因素分析相似。
  • 经颅多普勒微栓子检出率:癌症合并卒中组32%、单纯卒中组16%、单纯癌症组6%(p=0.005)。

关键数值与推荐

  • 血液生物标志物包括凝血标志物(D-二聚体和凝血酶-抗凝血酶)、血小板功能标志物(P-选择素)及内皮完整性标志物(血栓调节蛋白、可溶性细胞间黏附分子-1[sICAM-1]、可溶性血管细胞黏附分子-1[sVCAM-1])。
  • 生物标志物组间比较采用Kruskal-Wallis检验与Wilcoxon秩和检验。
  • 多因素线性回归模型 adjusted for 种族、卒中危险因素数量、吸烟、卒中严重程度及抗血栓药物使用。
  • 经颅多普勒微栓子存在情况组间比较采用卡方检验。

临床怎么用

  • 对活动性实体瘤合并急性缺血性卒中患者,可关注D-二聚体、sICAM-1、sVCAM-1、血栓调节蛋白及P-选择素等标志物。
  • 经颅多普勒微栓子检测有助于识别癌症相关卒中患者的循环微栓子增多状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to examine the pathophysiology of ischemic stroke with cancer. METHODS: We conducted a prospective cross-sectional study from 2016 to 2020 at 2 hospitals. We enrolled 3 groups of 50 adult participants each. The main group included patients with active solid tumor cancer and acute ischemic stroke. The control groups included patients with acute ischemic stroke only or active cancer only. The patients with stroke-only and patients with cancer-only were matched to the patients with cancer-plus-stroke by age, sex, and cancer type, if applicable. The outcomes were prespecified hematological biomarkers and transcranial Doppler microemboli detection. Hematological biomarkers included markers of coagulation (D-dimer and thrombin-antithrombin), platelet function (P-selectin), and endothelial integrity (thrombomodulin, soluble intercellular adhesion molecule-1 [sICAM-1], and soluble vascular cell adhesion molecule-1 [sVCAM-1]). Hematological biomarkers were compared between groups using the Kruskal-Wallis and Wilcoxon Rank-Sum tests. In multivariable linear regression models, we adjusted for race, number of stroke risk factors, smoking, stroke severity, and antithrombotic use. Transcranial Doppler microemboli presence was compared between groups using chi-square tests. RESULTS: Levels of all study biomarkers were different between groups. In univariate between-group comparisons, patients with cancer-plus-stroke had higher levels of D-dimer, sICAM-1, sVCAM-1, and thrombomodulin than both control groups; higher levels of thrombin-antithrombin than patients with cancer-only; and higher levels of P-selectin than patients with stroke-only. Findings were similar in multivariable analyses. Transcranial Doppler microemboli were detected in 32% of patients with cancer-plus-stroke, 16% of patients with stroke-only, and 6% of patients with cancer-only (p = 0.005). INTERPRETATION: Patients with cancer-related stroke have higher markers of coagulation, platelet, and endothelial dysfunction, and more circulating microemboli, than matched controls. ANN NEUROL 2021;90:159-169.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Navi BB, Sherman CP, Genova R, et al. Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective Study. Ann Neurol. 2021. PMID: 34029423. doi:10.1002/ana.26129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。